Article Sidebar

pdf
Date Published: 09/07/2024
Online Published: 31/12/2023
Abstract Views: 11
Views pdf: 2
DOI: https://doi.org/10.55046/vjrnm.53.949.2023
Issue
No. 53 (2023)
Section
Scientific research
How to Cite
Đức, B., Phạm, V. T., & Bùi, T. C. (2023). To evaluate the relationship between FDG PET/CT imaging characteristics and EGFR mutation status in patients with stage IV non-small cell lung cancer. Vietnamese Journal of Radiology and Nuclear Medicine, 53, 48-54. https://doi.org/10.55046/vjrnm.53.949.2023

To evaluate the relationship between FDG PET/CT imaging characteristics and EGFR mutation status in patients with stage IV non-small cell lung cancer.

Van Duc Bui1,, Van Thai Pham2, Tien Cong Bui3
1 Bệnh viện Bãi Cháy
2 Bach Mai hospital
3 Bach Mai Hospital

Main Article Content

Abstract

Aim: To evaluate the relationship between FDG PET/CT imaging characteristics and EGFR mutation status in patients with stage IV non-small cell lung cancer.


Subjects and research method: 108 patients with stage IV non-small cell lung cancer underwent FDG PET/CT scan, EGFR test before treatment from January 2018 to November 2020.


Result: The mean age was 62.1±9.2 (37 - 83), male (61.1%) female (38.9%), history of smoking (39.8%), stage IVa (31.5%) and stage IVb (68.5). 52.8% of the patients had EGFR mutation, in which exon 19 and exon 21 mutations are the highest with the rate of 31.5% and 18.5%. 48.1% of the patients received chemotherapy, 35.2% of patients on target treatment TKI Gender, smoking history, pSUVmax, tumor size are four independent predictors of EGFR gene mutation with OR 0.19, respectively (95% CI: 0.08-0.45; p<0.001);0.347 (95CI: 0,156-0,770; p=0.009); 0,0.805 (95% CI: 0.722-0.899; p<0.001) and 0.95 (95% CI: 0.911-0.993; p=0.022).


Conclusion: FDG PET/CT is valuable for predicting EGFR mutation levels in patients with non-small cell lung carcinoma.

Article Details

Keywords

Keywords: Lung cancer, adenocarcinoma, FDG PET/CT, prediction, EGFR mutation.

References

1. Sharma SV, Bell DW, Haber DA, (2007). Epidemal growth factor receptor mutations in lung cancer. Nat Rev Cancer,7:169–181.
2. Vanneman M, Dranoff G. (2012). Combining immunotherapy and targeted therapies in cancer treatment.Nat Rev Cancer,12(4):237–251.
3. Mai Trọng Khoa (2012), Y học hạt nhân, Sách dùng cho sau đại học NXB Y học.
4. Vũ Hữu Khiêm (2017), Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ bằng phác đồ hóa-xạ trị với kỹ thuật PET/CT mô phỏng, Luận án tiến sĩ y học, Trường Đại học Y Hà Nội.
5. Lê Viết Nam và Phạm Cẩm Phương (2021). Đánh giá kết quả hóa trị phác đồ có Pemetrexed ở bệnh nhân ung phổi không tế bào nhỏ giai đoạn IIIB-IV tại Bệnh viện Bạch Mai. VMJ, 506(2). 6. Phạm Thị Mai., Nguyễn Văn Ba., Hồ Hữu Thọ. và cộng sự. (2021). Đột biến gen EGFR và mối liên quan với một số yếu tố lâm sàng ở bệnh nhân ung thư biểu mô tuyến phổi. tcncyh, 137(1), 111–117.
7. Mak R.H., Digumarthy S.R., Muzikansky A. và cộng sự. (2011). Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Oncologist, 16(3), 319–326.
8. Gu J., Xu S., Huang L. và cộng sự. (2018). Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer. J Thorac Dis, 10(2), 723–731.
9. Cho A., Hur J., Moon Y.W. và cộng sự. (2016). Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer, 16, 224.